Home › Companies › LIGAND PHARMACEUTICALS INC. › 2024-2025

LIGAND PHARMACEUTICALS INC. 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings and LIGAND PHARMACEUTICALS INC.’s Form 8-K, filed June 9, 2025 (Item 5.07 on EDGAR). Page generated October 18, 2026.

11Reported items
332Asset managers
3,606Fund votes
June 6, 2025Meeting date

Results at a glance

Meeting of June 6, 2025: 10 items on LIGAND PHARMACEUTICALS INC.’s Form 8-K, filed June 9, 2025: 8 elected · 2 approved.

Material dissent

None.

Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore LIGAND PHARMACEUTICALS INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by LIGAND PHARMACEUTICALS INC.

These tallies are LIGAND PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 9, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

LIGAND PHARMACEUTICALS INC. — official shareholder meeting results, meeting held June 6, 2025
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Support (of votes cast)	Reported outcome	Voting standard
Elect Director: Jason M. Aryeh	13,595,137	--	--	3,224,879	1,363,582	81%	Elected	—
Elect Director: Todd C. Davis	16,393,716	--	--	426,300	1,363,582	97%	Elected	—
Elect Director: Nancy R. Gray, Ph.D.	16,470,033	--	--	349,983	1,363,582	98%	Elected	—
Elect Director: Jason Haas	16,621,292	--	--	198,724	1,363,582	99%	Elected	—
Elect Director: John W. Kozarich, Ph.D.	15,684,962	--	--	1,135,054	1,363,582	93%	Elected	—
Elect Director: John L. LaMattina, Ph.D.	15,961,637	--	--	858,379	1,363,582	95%	Elected	—
Elect Director: Stephen L. Sabba, M.D.	15,789,883	--	--	1,030,133	1,363,582	94%	Elected	—
Elect Director: Martine Zimmermann, Pharm.D.	16,666,655	--	--	153,361	1,363,582	99.0%	Elected	—
2. The ratification of the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025	17,274,429	906,847	2,322	--	--	95%	Approved	—
3. The approval of a non-binding advisory resolution regarding the compensation of the Company's named executive officers	15,576,200	1,183,843	59,973	--	1,363,582	93%	Approved	—

Source: LIGAND PHARMACEUTICALS INC., Form 8-K, filed with the SEC on June 9, 2025 — read the filing on EDGAR.

How asset managers voted at the LIGAND PHARMACEUTICALS INC. 2024-2025 meeting

Each item below shows how the 332 asset managers that disclosed a LIGAND PHARMACEUTICALS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of LIGAND PHARMACEUTICALS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. Elect Director: Jason Haas

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 6 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%

FOR: 16,621,292WITHHELD: 198,724

Details: description as filed, official tally, votes by 99 asset managers

Description as filed by funds: Election of Directors: Jason Haas

LIGAND PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Jason Haas”): 16,621,292 for, 198,724 withheld, per its Form 8-K filed June 9, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “In accordance with the results below, each nominee was elected to serve as a director of the Company.”
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 99 asset managers below reported 10,267,604 for, 0 abstained.

FOR

FOR: 10,267,604ABSTAIN: 0

Largest asset managers voting on “Election of Directors: Jason Haas” at LIGAND PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Vote
Vanguard	2,348,140	For
BlackRock	1,740,918	For
JANUS INVESTMENT FUND	889,850	For
Delaware/Macquarie	689,703	For
Dimensional	408,856	For
Fidelity	405,401	For
PROFESSIONALLY MANAGED PORTFOLIOS	383,338	For
State Street	285,288	For
MFS	281,879	For
IMPAX FUNDS SERIES TRUST I	280,208	For
DWS	276,745	For
Loomis Sayles	240,684	For
Franklin Custodian Funds	160,000	For
Charles Schwab	153,807	For
BUFFALO FUNDS	135,482	For
Columbia Threadneedle	122,052	For
Bridge Builder Trust	100,563	For
Aberdeen	93,303	For
Allspring	71,495	For
Lincoln Financial	70,127	For
Invesco	60,753	For
Calamos	56,344	For
Russell Investments	53,952	For
Brighthouse	51,331	For
First Trust	49,348	For

Showing the 25 largest of 99 asset managers. See all 99 in the interactive database.

2. Elect Director: Jason M. Aryeh

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 6 wordings of this item as funds reported it.

81% Majority: yes · of votes cast

FOR 81%WITHHELD

FOR: 13,595,137WITHHELD: 3,224,879

Details: description as filed, official tally, votes by 99 asset managers

Description as filed by funds: Election of Directors: Jason M. Aryeh

LIGAND PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Jason M. Aryeh”): 13,595,137 for, 3,224,879 withheld, per its Form 8-K filed June 9, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “In accordance with the results below, each nominee was elected to serve as a director of the Company.”
Support: 81% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 99 asset managers below reported 8,766,116 for, 1,217,155 withheld, 284,333 abstained.

FOR

FOR: 8,766,116ABSTAIN: 284,333WITHHOLD: 1,217,155

Largest asset managers voting on “Election of Directors: Jason M. Aryeh” at LIGAND PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Abstain	Withheld	Vote
Vanguard	2,347,098	5	1,037	For
BlackRock	1,740,918	0	0	For
JANUS INVESTMENT FUND	889,850	0	0	For
Delaware/Macquarie	0	0	689,703	Withhold
Dimensional	408,856	0	0	For
Fidelity	405,401	0	0	For
PROFESSIONALLY MANAGED PORTFOLIOS	383,338	0	0	For
State Street	285,270	0	18	For
MFS	281,879	0	0	For
IMPAX FUNDS SERIES TRUST I	280,208	0	0	For
DWS	276,745	0	0	For
Loomis Sayles	0	240,684	0	Abstain
Franklin Custodian Funds	160,000	0	0	For
Charles Schwab	153,807	0	0	For
BUFFALO FUNDS	135,482	0	0	For
Columbia Threadneedle	0	0	122,052	Withhold
Bridge Builder Trust	100,308	255	0	For
Aberdeen	0	0	93,303	Withhold
Allspring	71,495	0	0	For
Lincoln Financial	26,518	0	43,609	Mixed
Invesco	60,753	0	0	For
Calamos	56,344	0	0	For
Russell Investments	0	0	53,952	Withhold
Brighthouse	6,718	0	44,613	Mixed
First Trust	49,348	0	0	For

Showing the 25 largest of 99 asset managers. See all 99 in the interactive database.

3. Elect Director: John L. LaMattina, Ph.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 9 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%

FOR: 15,961,637WITHHELD: 858,379

Details: description as filed, official tally, votes by 99 asset managers

Description as filed by funds: Election of Directors: John L. LaMattina, Ph.D.

LIGAND PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: John L. LaMattina, Ph.D.”): 15,961,637 for, 858,379 withheld, per its Form 8-K filed June 9, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “In accordance with the results below, each nominee was elected to serve as a director of the Company.”
Support: 95% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 99 asset managers below reported 10,266,239 for, 958 withheld, 406 abstained.

FOR

FOR: 10,266,239ABSTAIN: 406WITHHOLD: 958

Largest asset managers voting on “Election of Directors: John L. LaMattina, Ph.D.” at LIGAND PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Abstain	Withheld	Vote
Vanguard	2,348,139	1	0	For
BlackRock	1,740,918	0	0	For
JANUS INVESTMENT FUND	889,850	0	0	For
Delaware/Macquarie	689,703	0	0	For
Dimensional	408,856	0	0	For
Fidelity	405,401	0	0	For
PROFESSIONALLY MANAGED PORTFOLIOS	383,338	0	0	For
State Street	285,270	0	18	For
MFS	281,879	0	0	For
IMPAX FUNDS SERIES TRUST I	280,208	0	0	For
DWS	276,745	0	0	For
Loomis Sayles	240,684	0	0	For
Franklin Custodian Funds	160,000	0	0	For
Charles Schwab	153,807	0	0	For
BUFFALO FUNDS	135,482	0	0	For
Columbia Threadneedle	122,052	0	0	For
Bridge Builder Trust	100,308	255	0	For
Aberdeen	93,303	0	0	For
Allspring	71,495	0	0	For
Lincoln Financial	70,127	0	0	For
Invesco	60,753	0	0	For
Calamos	56,344	0	0	For
Russell Investments	53,952	0	0	For
Brighthouse	51,331	0	0	For
First Trust	49,348	0	0	For

Showing the 25 largest of 99 asset managers. See all 99 in the interactive database.

4. Elect Director: John W. Kozarich, Ph.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 7 wordings of this item as funds reported it.

93% Majority: yes · of votes cast

FOR 93%

FOR: 15,684,962WITHHELD: 1,135,054

Details: description as filed, official tally, votes by 99 asset managers

Description as filed by funds: Election of Directors: John W. Kozarich, Ph.D.

LIGAND PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: John W. Kozarich, Ph.D.”): 15,684,962 for, 1,135,054 withheld, per its Form 8-K filed June 9, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “In accordance with the results below, each nominee was elected to serve as a director of the Company.”
Support: 93% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 99 asset managers below reported 10,170,088 for, 97,109 withheld, 407 abstained.

FOR

FOR: 10,170,088ABSTAIN: 407WITHHOLD: 97,109

Largest asset managers voting on “Election of Directors: John W. Kozarich, Ph.D.” at LIGAND PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Abstain	Withheld	Vote
Vanguard	2,347,102	2	1,037	For
BlackRock	1,740,918	0	0	For
JANUS INVESTMENT FUND	889,850	0	0	For
Delaware/Macquarie	689,703	0	0	For
Dimensional	408,856	0	0	For
Fidelity	405,401	0	0	For
PROFESSIONALLY MANAGED PORTFOLIOS	383,338	0	0	For
State Street	285,270	0	18	For
MFS	281,879	0	0	For
IMPAX FUNDS SERIES TRUST I	280,208	0	0	For
DWS	276,745	0	0	For
Loomis Sayles	240,684	0	0	For
Franklin Custodian Funds	160,000	0	0	For
Charles Schwab	153,807	0	0	For
BUFFALO FUNDS	135,482	0	0	For
Columbia Threadneedle	122,052	0	0	For
Bridge Builder Trust	100,308	255	0	For
Aberdeen	0	0	93,303	Withhold
Allspring	71,495	0	0	For
Lincoln Financial	70,127	0	0	For
Invesco	60,753	0	0	For
Calamos	56,344	0	0	For
Russell Investments	53,952	0	0	For
Brighthouse	51,331	0	0	For
First Trust	49,348	0	0	For

Showing the 25 largest of 99 asset managers. See all 99 in the interactive database.

5. Elect Director: Nancy R. Gray, Ph.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 7 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 16,470,033WITHHELD: 349,983

Details: description as filed, official tally, votes by 99 asset managers

Description as filed by funds: Election of Directors: Nancy R. Gray, Ph.D.

LIGAND PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Nancy R. Gray, Ph.D.”): 16,470,033 for, 349,983 withheld, per its Form 8-K filed June 9, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “In accordance with the results below, each nominee was elected to serve as a director of the Company.”
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 99 asset managers below reported 10,264,501 for, 2,848 withheld, 255 abstained.

FOR

FOR: 10,264,501ABSTAIN: 255WITHHOLD: 2,848

Largest asset managers voting on “Election of Directors: Nancy R. Gray, Ph.D.” at LIGAND PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Abstain	Withheld	Vote
Vanguard	2,347,103	0	1,037	For
BlackRock	1,740,918	0	0	For
JANUS INVESTMENT FUND	889,850	0	0	For
Delaware/Macquarie	689,703	0	0	For
Dimensional	408,856	0	0	For
Fidelity	405,401	0	0	For
PROFESSIONALLY MANAGED PORTFOLIOS	383,338	0	0	For
State Street	285,288	0	0	For
MFS	281,879	0	0	For
IMPAX FUNDS SERIES TRUST I	280,208	0	0	For
DWS	276,745	0	0	For
Loomis Sayles	240,684	0	0	For
Franklin Custodian Funds	160,000	0	0	For
Charles Schwab	153,807	0	0	For
BUFFALO FUNDS	135,482	0	0	For
Columbia Threadneedle	122,052	0	0	For
Bridge Builder Trust	100,308	255	0	For
Aberdeen	93,303	0	0	For
Allspring	71,495	0	0	For
Lincoln Financial	70,127	0	0	For
Invesco	60,753	0	0	For
Calamos	56,344	0	0	For
Russell Investments	53,952	0	0	For
Brighthouse	51,331	0	0	For
First Trust	49,348	0	0	For

Showing the 25 largest of 99 asset managers. See all 99 in the interactive database.

6. Elect Director: Stephen L. Sabba, M.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 7 wordings of this item as funds reported it.

94% Majority: yes · of votes cast

FOR 94%

FOR: 15,789,883WITHHELD: 1,030,133

Details: description as filed, official tally, votes by 99 asset managers

Description as filed by funds: Election of Directors: Stephen L. Sabba, M.D.

LIGAND PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Stephen L. Sabba, M.D.”): 15,789,883 for, 1,030,133 withheld, per its Form 8-K filed June 9, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “In accordance with the results below, each nominee was elected to serve as a director of the Company.”
Support: 94% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 99 asset managers below reported 10,172,936 for, 94,261 withheld, 407 abstained.

FOR

FOR: 10,172,936ABSTAIN: 407WITHHOLD: 94,261

Largest asset managers voting on “Election of Directors: Stephen L. Sabba, M.D.” at LIGAND PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Abstain	Withheld	Vote
Vanguard	2,348,138	2	0	For
BlackRock	1,740,918	0	0	For
JANUS INVESTMENT FUND	889,850	0	0	For
Delaware/Macquarie	689,703	0	0	For
Dimensional	408,856	0	0	For
Fidelity	405,401	0	0	For
PROFESSIONALLY MANAGED PORTFOLIOS	383,338	0	0	For
State Street	285,270	0	18	For
MFS	281,879	0	0	For
IMPAX FUNDS SERIES TRUST I	280,208	0	0	For
DWS	276,745	0	0	For
Loomis Sayles	240,684	0	0	For
Franklin Custodian Funds	160,000	0	0	For
Charles Schwab	153,807	0	0	For
BUFFALO FUNDS	135,482	0	0	For
Columbia Threadneedle	122,052	0	0	For
Bridge Builder Trust	100,308	255	0	For
Aberdeen	0	0	93,303	Withhold
Allspring	71,495	0	0	For
Lincoln Financial	70,127	0	0	For
Invesco	60,753	0	0	For
Calamos	56,344	0	0	For
Russell Investments	53,952	0	0	For
Brighthouse	51,331	0	0	For
First Trust	49,348	0	0	For

Showing the 25 largest of 99 asset managers. See all 99 in the interactive database.

7. Elect Director: Todd C. Davis

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 6 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%

FOR: 16,393,716WITHHELD: 426,300

Details: description as filed, official tally, votes by 99 asset managers

Description as filed by funds: Election of Directors: Todd C. Davis

LIGAND PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Todd C. Davis”): 16,393,716 for, 426,300 withheld, per its Form 8-K filed June 9, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “In accordance with the results below, each nominee was elected to serve as a director of the Company.”
Support: 97% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 99 asset managers below reported 10,253,686 for, 13,662 withheld, 256 abstained.

FOR

FOR: 10,253,686ABSTAIN: 256WITHHOLD: 13,662

Largest asset managers voting on “Election of Directors: Todd C. Davis” at LIGAND PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Abstain	Withheld	Vote
Vanguard	2,348,139	1	0	For
BlackRock	1,740,918	0	0	For
JANUS INVESTMENT FUND	889,850	0	0	For
Delaware/Macquarie	689,703	0	0	For
Dimensional	408,856	0	0	For
Fidelity	405,401	0	0	For
PROFESSIONALLY MANAGED PORTFOLIOS	383,338	0	0	For
State Street	285,270	0	18	For
MFS	281,879	0	0	For
IMPAX FUNDS SERIES TRUST I	280,208	0	0	For
DWS	276,745	0	0	For
Loomis Sayles	240,684	0	0	For
Franklin Custodian Funds	160,000	0	0	For
Charles Schwab	153,807	0	0	For
BUFFALO FUNDS	135,482	0	0	For
Columbia Threadneedle	122,052	0	0	For
Bridge Builder Trust	100,308	255	0	For
Aberdeen	93,303	0	0	For
Allspring	71,495	0	0	For
Lincoln Financial	70,127	0	0	For
Invesco	60,753	0	0	For
Calamos	56,344	0	0	For
Russell Investments	53,952	0	0	For
Brighthouse	51,331	0	0	For
First Trust	49,348	0	0	For

Showing the 25 largest of 99 asset managers. See all 99 in the interactive database.

8. Elect Director: Martine Zimmermann, Pharm.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 4 wordings of this item as funds reported it.

99.0% Majority: yes · of votes cast

FOR 99.0%

FOR: 16,666,655WITHHELD: 153,361

Details: description as filed, official tally, votes by 78 asset managers

Description as filed by funds: Election of Directors: Martine Zimmermann, Pharm.D.

LIGAND PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Martine Zimmermann, Pharm.D.”): 16,666,655 for, 153,361 withheld, per its Form 8-K filed June 9, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “In accordance with the results below, each nominee was elected to serve as a director of the Company.”
Support: 99.0% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 78 asset managers below reported 7,468,394 for.

FOR

FOR: 7,468,394

Largest asset managers voting on “Election of Directors: Martine Zimmermann, Pharm.D.” at LIGAND PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Vote
Vanguard	2,346,569	For
JANUS INVESTMENT FUND	889,850	For
Delaware/Macquarie	689,703	For
Dimensional	408,856	For
Fidelity	405,401	For
State Street	285,288	For
MFS	281,879	For
IMPAX FUNDS SERIES TRUST I	280,208	For
DWS	276,745	For
Franklin Custodian Funds	160,000	For
Charles Schwab	153,807	For
Columbia Threadneedle	122,052	For
Aberdeen	93,303	For
Allspring	71,495	For
Lincoln Financial	70,127	For
Invesco	60,753	For
Russell Investments	53,952	For
Brighthouse	51,331	For
First Trust	49,348	For
Equitable	48,835	For
Pacific Life	46,995	For
AMERICAN BEACON FUNDS	46,013	For
TIAA	43,443	For
American Century	41,790	For
Northern Trust	29,970	For

Showing the 25 largest of 78 asset managers. See all 78 in the interactive database.

9. DIRECTOR: M. ZIMMERMANN, PHARM.D.

No official matchDIRECTOR ELECTIONS

Combines 3 wordings of this item as funds reported it.

100% of fund votes cast · no official result

FOR

Details: votes by 25 asset managers

The 25 asset managers below reported 2,799,210 for, 0 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 2,799,210ABSTAIN: 0

Largest asset managers voting on “DIRECTOR: M. ZIMMERMANN, PHARM.D.” at LIGAND PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Vote
BlackRock	1,740,918	For
PROFESSIONALLY MANAGED PORTFOLIOS	383,338	For
Loomis Sayles	240,684	For
BUFFALO FUNDS	135,482	For
Bridge Builder Trust	100,563	For
Calamos	56,344	For
Jackson National	37,431	For
AMG FUNDS	30,517	For
QUANTITATIVE MASTER SERIES LLC	18,407	For
JPMorgan	18,306	For
TIFF INVESTMENT PROGRAM	10,242	For
John Hancock	7,472	For
Allianz	6,750	For
PFM Multi-Manager Series Trust	3,313	For
TIMOTHY PLAN	2,960	For
Pacer Funds Trust	2,597	For
Vanguard	1,571	For
RBB FUND, INC.	978	For
UNIFIED SERIES TRUST	864	For
GPS Funds I	161	For
Innovator ETFs Trust	150	For
Advisors' Inner Circle Fund III	76	For
WILSHIRE MUTUAL FUNDS INC	50	For
RBB Fund Trust	34	For
NORTHERN LIGHTS FUND TRUST II	2	For

10. 3. The approval of a non-binding advisory resolution regarding the compensation of the Company's named executive…

Official result Fund totals may overlapCOMPENSATIONReported outcome: Approved

Combines 8 wordings of this item as funds reported it.

93% Approved · of votes cast

FOR 93%

FOR: 15,576,200AGAINST: 1,183,843

Details: description as filed, official tally, votes by 332 asset managers

Description as filed by funds: Approval, on an advisory basis, of the compensation of the named executive officers

LIGAND PHARMACEUTICALS INC.’s own tally for this item (“3. The approval of a non-binding advisory resolution regarding the compensation of the Company's named executive officers”): 15,576,200 for, 1,183,843 against — passed, per its Form 8-K filed June 9, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “In accordance with the results below, the proposal was approved.”
Support: 93% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 100 asset managers voting on “Approval, on an advisory basis, of the compensation of the named executive officers” at LIGAND PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Against	Vote
Vanguard	2,347,102	1,038	For
BlackRock	1,740,918	0	For
JANUS INVESTMENT FUND	889,850	0	For
Delaware/Macquarie	689,703	0	For
Dimensional	408,856	0	For
Fidelity	405,401	0	For
PROFESSIONALLY MANAGED PORTFOLIOS	383,338	0	For
State Street	285,158	130	For
MFS	281,879	0	For
IMPAX FUNDS SERIES TRUST I	280,208	0	For
DWS	276,745	0	For
Loomis Sayles	240,684	0	For
Franklin Custodian Funds	160,000	0	For
Charles Schwab	153,807	0	For
BUFFALO FUNDS	135,482	0	For
Columbia Threadneedle	0	122,052	Against
Bridge Builder Trust	100,308	255	For
Aberdeen	0	93,303	Against
Allspring	71,495	0	For
Lincoln Financial	70,127	0	For
Invesco	0	60,753	Against
Calamos	56,344	0	For
Russell Investments	53,952	0	For
Brighthouse	51,331	0	For
First Trust	49,348	0	For

Fund voting reports, all 100 managers: 9,961,097 for, 331,251 against, 0 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 259 asset managers voting on “Approval, on an advisory basis, of the compensation of the named executive officers” at LIGAND PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Against	Vote
Janus Henderson	987,087	4,185	For
MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST	840,083	0	For
State Street	644,975	6,761	For
CONGRESS ASSET MANAGEMENT CO	553,551	0	For
Stephens Investment Management Group LLC	484,171	0	For
BlackRock	435,529	7,286	For
GEODE CAPITAL MANAGEMENT, LLC	426,507	0	For
Loomis Sayles	382,265	28,088	Mixed
Chicago Capital, LLC	342,298	0	For
MASSACHUSETTS FINANCIAL SERVICES CO /MA/	319,767	0	For
IMPAX ASSET MANAGEMENT LLC	280,208	0	For
ASHFORD CAPITAL MANAGEMENT INC	279,072	0	For
VILLERE ST DENIS J & CO LLC	262,870	0	For
Northern Trust	236,071	879	For
RICE HALL JAMES & ASSOCIATES, LLC	236,006	0	For
Ranger Investment Management, L.P.	215,330	0	For
Aberdeen	0	202,487	Against
FRANKLIN ADVISERS INC	182,853	0	For
Charles Schwab	172,110	0	For
Private Capital Management, LLC	149,341	0	For
Russell Investments	117,020	0	For
Granite Investment Partners, LLC	109,839	0	For
MELLON INVESTMENTS Corp	103,973	0	For
PRINCIPAL GLOBAL INVESTORS	103,186	0	For
DRIEHAUS CAPITAL MANAGEMENT LLC	98,056	0	For

Institutional-manager reports, all 259 managers: 9,364,710 for, 840,394 against, 268 abstained, 385 not voted. Showing the 25 largest; see all in the interactive database.

11. 2. The ratification of the selection of Ernst & Young LLP as the Company's independent registered public accounting…

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 3 wordings of this item as funds reported it.

95% Approved · of votes cast

FOR 95%

FOR: 17,274,429AGAINST: 906,847

Details: description as filed, official tally, votes by 100 asset managers

Description as filed by funds: Ratification of Ernst & Young LLP as Ligand's independent registered accounting firm for the fiscal year ending December 31, 2025

LIGAND PHARMACEUTICALS INC.’s own tally for this item (“2. The ratification of the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025”): 17,274,429 for, 906,847 against — passed, per its Form 8-K filed June 9, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “In accordance with the results below, the selection of Ernst & Young LLP was ratified.”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of LIGAND PHARMACEUTICALS INC.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Ratify Appointment of Independent Auditors” (3 managers, 14,091 for).

The 100 asset managers below reported 10,258,135 for, 9,891 against, 0 abstained.

FOR

FOR: 10,258,135AGAINST: 9,891ABSTAIN: 0

Largest asset managers voting on “Ratification of Ernst & Young LLP as Ligand's independent registered accounting firm for the fiscal year endin” at LIGAND PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Against	Vote
Vanguard	2,348,139	1	For
BlackRock	1,740,918	0	For
JANUS INVESTMENT FUND	889,850	0	For
Delaware/Macquarie	689,703	0	For
Dimensional	408,856	0	For
Fidelity	405,401	0	For
PROFESSIONALLY MANAGED PORTFOLIOS	383,338	0	For
State Street	285,270	18	For
MFS	281,879	0	For
IMPAX FUNDS SERIES TRUST I	280,208	0	For
DWS	276,745	0	For
Loomis Sayles	240,684	0	For
Franklin Custodian Funds	160,000	0	For
Charles Schwab	153,807	0	For
BUFFALO FUNDS	135,482	0	For
Columbia Threadneedle	122,052	0	For
Bridge Builder Trust	100,563	0	For
Aberdeen	93,303	0	For
Allspring	71,495	0	For
Lincoln Financial	70,127	0	For
Invesco	60,753	0	For
Calamos	56,344	0	For
Russell Investments	53,952	0	For
Brighthouse	51,331	0	For
First Trust	49,348	0	For

Showing the 25 largest of 100 asset managers. See all 100 in the interactive database.

Largest LIGAND PHARMACEUTICALS INC. shareholders voting in 2024-2025

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 19,276,000 shares outstanding at the time of that meeting.

Fund voting reports: top LIGAND PHARMACEUTICALS INC. shareholders by shares voted on “Approval, on an advisory basis, of the compensation of the named executive officers”, 2024-2025
#	Asset manager	% of shares outstanding
1	Vanguard	12.18%
2	BlackRock	9.03%
3	JANUS INVESTMENT FUND	4.62%
4	Delaware/Macquarie	3.58%
5	Dimensional	2.12%
6	Fidelity	2.10%
7	PROFESSIONALLY MANAGED PORTFOLIOS	1.99%
8	State Street	1.48%
9	MFS	1.46%
10	IMPAX FUNDS SERIES TRUST I	1.45%

Institutional-manager reports: top LIGAND PHARMACEUTICALS INC. shareholders by shares voted on “Approval, on an advisory basis, of the compensation of the named executive officers”, 2024-2025
#	Asset manager	% of shares outstanding
1	Janus Henderson	5.14%
2	MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST	4.36%
3	State Street	3.38%
4	CONGRESS ASSET MANAGEMENT CO	2.87%
5	Stephens Investment Management Group LLC	2.51%
6	BlackRock	2.30%
7	GEODE CAPITAL MANAGEMENT, LLC	2.21%
8	Loomis Sayles	2.13%
9	Chicago Capital, LLC	1.78%
10	MASSACHUSETTS FINANCIAL SERVICES CO /MA/	1.66%

Reported LIGAND PHARMACEUTICALS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.

LIGAND PHARMACEUTICALS INC. holdings and ownership disclosed for the 2024-2025 proxy season
Holder	% outstanding	Disclosure
Ligand Pharmaceuticals Incorporated	41.83%	13D
BlackRock	15.15%	13F
Vanguard Group	10.66%	13F
Vanguard Portfolio Management	5.75%	13G
JANUS HENDERSON GROUP PLC	5.41%	13G
Dimensional Fund Advisors	3.86%	13F
State Street	3.77%	13F
Todd C. Davis	1.63%	DEF14A
Matthew Korenberg	1.58%	DEF14A
Northern Trust	1.52%	13F

Percentages above are of 19,276,000 shares outstanding, as reported by LIGAND PHARMACEUTICALS INC. on its Form 10-Q dated March 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from LIGAND PHARMACEUTICALS INC.’s 10-Q dated March 31, 2025. This page is a static snapshot rebuilt weekly on October 18, 2026; a live search always shows the current data.

At LIGAND PHARMACEUTICALS INC.'s shareholder meeting held June 6, 2025, in the 2024-2025 proxy season, 332 asset managers reported how they voted in their SEC Form N-PX filings, covering 3,606 separate fund positions. Their filings are grouped here into 11 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — Approval, on an advisory basis, of the compensation of the named executive officers — LIGAND PHARMACEUTICALS INC.'s filing reports the proposal as approved, with 93% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: LIGAND PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 9, 2025.

LIGAND PHARMACEUTICALS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.

Download data (CSV): ballot items · votes by manager · column guide.